SBIR/STTR Research Award
IMMUNOTOXIN TREATMENT OF BLEPHAROSPASM AND STRAABISMUS
Award amount
$50,000Program and phase
SBIR · Phase IAward year
1992Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- Houston Biotechnology, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
BLEPHAROSPASM AND STRABISMUS ARE CHRONIC, DEBILITATING, OCULAR SPASTIC DISORDERS CAUSED BY UNCONTROLLED OR BALANCED MUSCLE CONTRACTION. THE LONG-TERM OBJECTIVE OF THIS WORK IS TO CREATE A THERAPEUTIC AGENT THAT WILL ABLATE CHOLINERGIC NEURONS RESPONSIBLE FOR THE MUSCLE CONTRACTION IN BLEPHAROSPASM AND STRABISMUS, AND TO TREAT HUMANS WITH THESE CONDITIONS. THE SPECIFIC AIMS INPHASE I ARE TO PRODUCE A HYBRIDOMA THAT SECRETES MONOCLONAL ANTIBODIES AGAINST A SPECIFIC CHOLINERGIC, NERVE TERMINAL MOLECULE, AND TO THEN CREATE AN IMMUNOTOXIN BY CONJUGATING THE MONOCLONAL ANTIBODY TO RICIN A TOXIN. WHEN ADMINISTERED, THE IMMUNOTOXIN WILL BECOME INTERNALIZED IN THE CHOLINERGIC NERVE TERMINAL AND KILL THE CHOLINERGIC NERVE. THIS APPROACH HAS AN ADVANTAGE OVER PRESENT TREATMENTS IN THAT FEWER TREATMENTS WILL BE NEEDED AND THERE MAY BE A PERMANENT CURE. THERE ARE A NUMBER OF OTHER RELATED, NON-OCULAR SPASTIC DISORDERS FOR WHICH THIS IMMUNOTOXIN COULD ALSO BE USED. THIS IS THE FIRST TIME AN IMMUNOTOXIN HAS BEEN DEVISED TO TREAT THESE DISORDERS.
Technology keywords
Not reported